Latest Breaking News On - Keynote 177 study - Page 1 : comparemela.com

Pembrolizumab continued to demonstrate at trend toward improved overall survival compared with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.

United kingdomCity ofPembrolizumab keytrudaNational health service foundationUniversity college hospitalKeen shiuNational health service foundation trustShiuk kMetastatic colorectal cancerKeynote 177 studyAtional health service foundation trustKai keen shiu